Seppic injectable polysorbates Montanox™ 80 PPI and Montanox™ 20 PPI are now compliant in the Chinese market

Share
  • May 18, 2021
  • 1 min of read time

Seppic injectable polysorbates Montanox™ 80 PPI and Montanox™ 20 PPI are now compliant in the Chinese market

Montanox™ 80 PPI et Montanox™ 20 PPI, ingredients developed and produced by Seppic, comply with the current Chinese pharmacopoeia and will be marketed in China from May 2021. 

As a supplier of specialty healthcare ingredients, Seppic is active in the parenteral excipients market with various solutions including its Montanox™ range of polysorbates acting as solubilizers or stabilizers.

The parenteral excipients market is growing at a rate of 10% per year, due to the increasing number of biologics requiring parenteral administration and the increasing number of active ingredients with low solubility, requiring a solubilizer to achieve an effective formulation.

The Montanox™ injectable range is used to solubilize pharmaceutical and/or biological active ingredients and to formulate oil-in-water emulsions.

Montanox™ 80 PPI and Montanox™ 20 PPI are the result of Seppic's expertise in manufacturing high purity excipients that meet the highest European Good Manufacturing Practice ("EU GMP part II") standards. With its excipients, Seppic offers the highest level of safety and reliability to its customers worldwide.

Célia Hérou, Market Manager for Pharmaceuticals at Seppic, states : "By being compliant to this Chinese Pharmacopoeia, we are meeting the increased regulatory requirements and demands of the global pharmaceutical market. Seppic's strength is that we control all stages of product manufacturing, following GMP."

Seppic CP Cover

Press release dated May 18, 2021

  • May 18, 2021
  • PDF - 140.56 KB
Download